Evaluation of Musculoskeletal Aging and Related Disorders Via Advanced Clinical Imaging

NCT07474571 · tracked via the Priya Life Science China tracker

Sponsor

Peking University People's Hospital

Phase

Observational

Started

2005-11-01

Last updated

2026-03-19

Condition(s) studied

OsteoarthitisOsteoporosis

Investigational drug(s) / intervention(s)

No Interventions

No Interventions: No Interventions

Study summary

Study Overview This clinical research focuses on the development and validation of a multimodal artificial intelligence (AI) platform designed for the automated diagnosis and precise staging of two major musculoskeletal conditions: Osteoporosis (OP) and Osteoarthritis (OA). By integrating diverse clinical imaging data, the study aims to provide a more objective and standardized approach to assessing bone and joint degeneration.

Technological Core: Intelligent Staging

Traditional diagnosis often relies on manual interpretation, which can lead to inter-observer variability. This study employs deep learning and multimodal imaging to:

For Osteoporosis: Automatically quantify bone mineral density and micro-architectural changes to determine the stage of bone loss and evaluate fracture risk.

For Osteoarthritis: Identify subtle radiological markers such as joint space narrowing and osteophyte formation to categorize the severity of joint degeneration according to international staging standards (e.g., Kellgren-Lawrence scale).

Why This Matters Early Intervention: By identifying early-stage changes in bone density and joint integrity, clinicians can implement preventive treatments before significant disability occurs.

Standardized Care: The intelligent diagnostic model provides a "digital second opinion," ensuring consistent staging across different healthcare settings.

Efficiency: The automated workflow reduces the workload of radiologists while maintaining high diagnostic accuracy.

Ethical Compliance The study is conducted at Peking University People's Hospital under the supervision of the Institutional Review Board (Approval No. 2026PHB097-001). It strictly adheres to international ethical standards, including the Declaration of Helsinki and Good Clinical Practice (GCP) guidelines, to ensure patient data privacy and safety.

Eligibility

Sex

ALL

Min age

18 Years

Max age

—

Healthy volunteers

Accepted

Inclusion Criteria: * Age: Adults aged at least 18 years. * Gender: No gender restrictions; both male and female participants are eligible. * Imaging Data: Participants must have completed relevant clinical imaging scans of skeletal sites, including but not limited to X-ray, CT (plain scan), or MRI (plain scan). * Anatomical Integrity: The skeletal structure of the target area must be free from congenital or acquired deformities. * Absence of Implants: No internal fixation materials or orthopedic implants in the skeletal areas being assessed. Exclusion Criteria: * Pathological History: Patients with a history of prior pathological fractures. * Malignancy: Patients seeking treatment or diagnosed with bone tumors or other systemic malignancies. * Medication History: Patients with a history of long-term steroid use, which may significantly affect bone density and joint structure. * Recent Treatment: Patients who have undergone radiotherapy or chemotherapy within the past six months. * Data Quality: Patients whose imaging data is of insufficient quality for AI analysis or lacks clear clinical diagnostic "gold standard" references (e.g., missing DXA results for osteoporosis staging).

Primary outcome measure(s)

Bone age status — From enrollment to the initial treatment at 2 years
Bone mineral density and osteoarthitis

Trial sites (1)

Facility	City	Region	Status
—	Beijing	China	Recruiting

More Peking University People's Hospital trials in China

Cadherin 3(CDH3)-Targeted PET in Lung Malignant Tumors Recruiting

Research on the Application of Patient Navigation-based Management Model of Patients After LEEP Starting soon

IFN-α in Relapse Prevention. Starting soon

ctDNA-Guided De-Escalation of Adjuvant Chemotherapy With Dalpiciclib in HR-Positive/HER2-Negative Breast Cancer Recruiting

CDK4/6 Inhibitors Combined With Endocrine Therapy for Neoadjuvant Treatment Recruiting

Other trials for the same condition

Evaluation of Efficacy and Safety of Prolia in Subjects of Male Osteoporosis in Mainland China Active, not recruiting

Epidemiological Study of Osteoporosis in the Elderly Population of Shandong Province Recruiting

Robot Assisted Minimally Invasive Treatment Versus Conventional Surgery for FFP3-4 Fragility Fractures of the Pelvis in Elderly Patients Starting soon

The Effect of Semaglutide on Bone Health Starting soon

Compare the Pharmacokinetics, Pharmacodynamics, Safety and Immunogenicity of SAL023 and Italy-Manufactured Evenity in Healthy Subjects Enrolling by invitation

Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT07474571 on ClinicalTrials.gov ↗ ← All trials in China